A5040162534- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Neuroendocrine Tumor Research Advances
- Gastrointestinal motility and disorders
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Medical Imaging and Pathology Studies
- Neurobiology and Insect Physiology Research
- Fungal Plant Pathogen Control
- Pain Management and Opioid Use
- Hepatocellular Carcinoma Treatment and Prognosis
- Insect and Pesticide Research
- Tracheal and airway disorders
- Cancer Diagnosis and Treatment
- Glycosylation and Glycoproteins Research
- X-ray Diffraction in Crystallography
- Gastroesophageal reflux and treatments
- Mycobacterium research and diagnosis
- Pain Mechanisms and Treatments
Hokkaido hospital
2016-2025
Japan Community Healthcare Organization
2017-2025
Sumitomo Chemical (Japan)
2012-2024
Takara (Japan)
2019-2024
RIKEN Center for Biosystems Dynamics Research
2022
Hokkaido University Hospital
2022
Hitachi (Japan)
2017
Kyoto University
2005-2015
Osaka Institute of Technology
2014
Japan Anti Tuberculosis Association
2013
Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little known about how its efficacy and safety profile compares that standard chemotherapy.We randomly assigned 230 patients metastatic, non-small-cell who had not previously received chemotherapy receive gefitinib or carboplatin-paclitaxel. The primary end point was progression-free survival; secondary points...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with cytotoxic chemotherapy is highly effective for the treatment of advanced non-small-cell lung cancer (NSCLC) EGFR mutations; however, little known about efficacy and safety this combination compared that standard therapy EGFR- inhibitors alone.We randomly assigned 345 patients newly diagnosed metastatic NSCLC mutations to gefitinib carboplatin plus pemetrexed or alone. Progression-free survival (PFS), PFS2,...
In recent years, many novel nontuberculous mycobacterial species have been discovered through genetic analysis. Mycobacterium massiliense and M. bolletii recently identified as separate from abscessus. However, little is known regarding their clinical microbiological differences in Japan. We performed a molecular identification of stored abscessus isolates for further identification. compared characteristics, radiological findings, treatment outcomes among patients with lung diseases. An...
Purpose Opioid-induced constipation (OIC) is a frequent and debilitating adverse effect (AE) of opioids-common analgesics for cancer pain. We investigated the efficacy safety peripherally acting μ-opioid receptor antagonist, naldemedine (S-297995), OIC, specifically in patients with cancer. Patients Methods This phase III trial consisted 2-week, randomized, double-blind, placebo-controlled study (COMPOSE-4) an open-label, 12-week extension (COMPOSE-5). In COMPOSE-4, eligible adults OIC were...
9005 Background: Although EGFR-TKI alone has been a standard first-line treatment for pts with advanced NSCLC EGFR mutations, our phase II study (NEJ005) showed promising efficacy of GCP. NEJ009, an open-label, randomized III study, was conducted to evaluate the superiority GCP vs G in progression-free survival (PFS), PFS2, and overall (OS). Methods: Pts newly diagnosed stage III/IV/ recurrent harboring activating mutations (exon 19 deletion or exon 21 L858R) were 1:1 250 mg PO QD (G 250mg...
Although cancer cachexia is mainly characterized by persistent loss of body weight (BW), usually in response to a malignancy, the pathophysiology remains unresolved. To elucidate relationship between BW and other related clinical factors, we conducted nationwide, multi-institutional, prospective, observational study patients with advanced non-small cell lung (NSCLC).Treatment-naïve stage IV NSCLC an Eastern Cooperative Oncology Group performance status (PS) 0-2 were eligible. BW, handgrip...
IntroductionWe aimed to evaluate the efficacy and safety of nanoparticle albumin-bound (nab-) paclitaxel for previously treated patients with advanced NSCLC.MethodsIn this randomized, open-label, noninferiority phase 3 trial, we enrolled NSCLC cytotoxic chemotherapy. Patients were randomly allocated (1:1) receive docetaxel (60 mg/m2) on day 1 or nab-paclitaxel (100 days 1, 8, 15 a 21-day cycle. The primary end point was overall survival (OS) analyzed an intention-to-treat...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned coprimary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.In a randomized, open-label, phase III NEJ009 study, gefitinib plus chemotherapy significantly improved...
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease implicated as an independent risk factor for cancer. However, optimal treatment advanced cancer with IPF remains to be established. We performed randomised phase 3 trial (J-SONIC) assess the efficacy and safety of nintedanib plus chemotherapy (experimental arm) compared alone (standard-of-care nonsmall cell (NSCLC) IPF.Chemotherapy-naïve NSCLC patients were allocated receive carboplatin (area under curve 6 on day 1) nanoparticle...
BackgroundEvidence of post-COVID-19 condition (PCC) in the Alpha- and Delta-variant dominant waves is limited.MethodsIn a nationwide multicentre cohort study collaboration with 20 hospitals, we collected data using self-administered questionnaires electronic medical records participants aged or more diagnosed COVID-19, hospitalized between Apr 1 2021 Sept 30 2021, discharged alive. Descriptive statistics were analyzed for PCC mental health (HADS anxiety depression scores), comparing Alpa...
Abstract BACKGROUND The authors developed fluoroscopic real‐time tumor‐tracking radiation therapy (RTRT) by insertion of a gold marker using bronchofiberscopy to reduce uncertainties in organ motion and set‐up error external radiotherapy for moving tumors. purpose the current study was evaluate RTRT's feasibility lung carcinoma treatment. METHODS three‐dimensional position 1.0‐2.0 mm or near tumor detected two sets fluoroscopies every 0.03 seconds. treatment beam gated irradiate only when...
Abstract Background. For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than carboplatin plus paclitaxel but did not show any advantage in the North East Japan 002 study. This report describes quality of life (QoL) analysis that Methods. Chemotherapy-naïve sensitive EGFR-mutated, advanced NSCLC were randomized to receive or chemotherapy (carboplatin and paclitaxel)....
Delta-like protein 3 (DLL3) is a Notch ligand that has an important role in the tumorigenesis of small cell lung cancer (SCLC). Recently, rovalpituzumab tesirine (Rova-T), DLL3-targeted antibody-drug conjugate, been developed for treating SCLC. DLL3 transcriptional target achaete-scute homolog-1 (ASCL1) transcription factor, which involved pulmonary neuroendocrine development. However, relationship between and/or ASCL1 expression and clinical features SCLC remains unknown, especially...
Smoking may have multifactorial effects on asthma phenotypes, particularly in severe asthma. Cluster analysis has been applied to explore novel which are not based any a priori hypotheses.To phenotypes by cluster when including smoking patients with asthma.We recruited total of 127 subjects asthma, 59 current or ex-smokers, from our university hospital and its 29 affiliated hospitals/pulmonary clinics. Clinical variables obtained during 2-day stay were used for analysis. After clustering...
The efficacy and safety of naldemedine (a peripherally acting µ-opioid receptor antagonist) for opioid-induced constipation (OIC) in subjects with cancer was demonstrated the primary report a phase III, double-blind study (COMPOSE-4) its open-label extension (COMPOSE-5). end point, proportion spontaneous bowel movement (SBM) responders, met. Here, we results from secondary points, including quality life (QOL) assessments these studies.In COMPOSE-4, eligible adults OIC were randomly assigned...
Immune-checkpoint inhibitors (ICIs) are effective against advanced non-small cell lung cancer (NSCLC). However, whether the efficacy and safety of ICI treatment in elderly patients similar to those younger is unclear. This study was designed address this question.We enrolled who received monotherapy Japan between December 2015 2017; ≥75 years age comprised group. We compared with explored prognostic factors patients.We 676 patients; 137 (20.3%) were assigned The median groups 78 (range,...
Abstract Background Allergic bronchopulmonary aspergillosis (ABPA) develops in the presence or absence of asthma, either atopic nonatopic. We have tried to explore essential components pathogenesis disease, which are consistent and variable according type asthma. Methods Non‐cystic fibrosis ABPA cases satisfying Asano's criteria were extracted from a prospective registry related diseases Japan between 2013 2023. According preceding was classified into three groups: sans asthma (no asthma),...
Rationale: A fatal acute exacerbation (AE) occasionally develops during chemotherapy for small cell lung cancer (SCLC) with comorbid idiopathic pulmonary fibrosis (IPF).Objectives: This study aimed to assess the safety and efficacy of carboplatin, etoposide, nintedanib combination therapy unresectable SCLC IPF.Methods: The NEXT-SHIP is a multicenter, single-arm, phase 2 trial IPF (Japan Registry Clinical Trials registry number jRCTs031190119). patients received (150 mg twice daily). primary...